JP2018186815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018186815A5 JP2018186815A5 JP2018111489A JP2018111489A JP2018186815A5 JP 2018186815 A5 JP2018186815 A5 JP 2018186815A5 JP 2018111489 A JP2018111489 A JP 2018111489A JP 2018111489 A JP2018111489 A JP 2018111489A JP 2018186815 A5 JP2018186815 A5 JP 2018186815A5
- Authority
- JP
- Japan
- Prior art keywords
- vlp
- virus
- protein
- polynucleotide
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 241000710929 Alphavirus Species 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 6
- 102100021696 Syncytin-1 Human genes 0.000 claims 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims 5
- 101710091045 Envelope protein Proteins 0.000 claims 4
- 101710188315 Protein X Proteins 0.000 claims 4
- 241000714474 Rous sarcoma virus Species 0.000 claims 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 101710172711 Structural protein Proteins 0.000 claims 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 101710177291 Gag polyprotein Proteins 0.000 claims 2
- 108010093013 HLA-DR1 Antigen Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 241000710960 Sindbis virus Species 0.000 claims 2
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 1
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 101710145006 Lysis protein Proteins 0.000 claims 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 claims 1
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 claims 1
- 101710144127 Non-structural protein 1 Proteins 0.000 claims 1
- 101710144128 Non-structural protein 2 Proteins 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 1
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 claims 1
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 102100031056 Serine protease 57 Human genes 0.000 claims 1
- 101710197596 Serine protease 57 Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 101000936049 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Outer membrane lipoprotein Blc Proteins 0.000 claims 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003197 gene knockdown Methods 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108700004029 pol Genes Proteins 0.000 claims 1
- 101150088264 pol gene Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 208000005925 vesicular stomatitis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615687P | 2012-03-26 | 2012-03-26 | |
| US61/615,687 | 2012-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Division JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018186815A JP2018186815A (ja) | 2018-11-29 |
| JP2018186815A5 true JP2018186815A5 (enExample) | 2019-01-17 |
| JP6585237B2 JP6585237B2 (ja) | 2019-10-02 |
Family
ID=47998556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Pending JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
| JP2018111489A Active JP6585237B2 (ja) | 2012-03-26 | 2018-06-12 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Pending JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9506041B2 (enExample) |
| EP (2) | EP3663395B1 (enExample) |
| JP (2) | JP2015527296A (enExample) |
| AU (3) | AU2013240248B2 (enExample) |
| WO (1) | WO2013148302A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| US9506041B2 (en) | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| CN113648406A (zh) | 2013-12-16 | 2021-11-16 | 美利坚合众国, 由健康及人类服务部部长代表 | 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法 |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| CA2986051C (fr) * | 2015-05-15 | 2023-09-26 | Vectalys | Particule retrovirale comportant au moins deux arn non viraux encapsides |
| FR3036118B1 (fr) * | 2015-05-15 | 2019-07-12 | Flash Therapeutics | Particule retrovirale comportant au moins deux arn non viraux encapsides. |
| EP3310368B1 (en) | 2015-06-19 | 2025-07-16 | LGC Clinical Diagnostics, Inc. | Sindbis control virus |
| JP2018530314A (ja) | 2015-08-28 | 2018-10-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ウイルス様粒子からの感染性インフルエンザウイルスの生成 |
| CA3004132A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| WO2017143236A1 (en) | 2016-02-19 | 2017-08-24 | Yoshihiro Kawaoka | Improved influenza b virus replication for vaccine development |
| KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | Univ Queensland | moléculas quiméricas e usos das mesmas |
| EP4400174A3 (en) | 2017-09-01 | 2024-10-23 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| CA3092372A1 (en) | 2018-02-26 | 2019-08-29 | AnTolRx, Inc. | Tolerogenic liposomes and methods of use thereof |
| JP7306721B2 (ja) * | 2018-07-13 | 2023-07-11 | 国立大学法人京都大学 | ウイルス様粒子及びその使用 |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| WO2020223205A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| US20200390718A1 (en) | 2019-05-28 | 2020-12-17 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US20220396806A1 (en) | 2019-07-26 | 2022-12-15 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| JP2023526047A (ja) | 2020-05-13 | 2023-06-20 | アコーオス インコーポレイテッド | Ｓｌｃ２６ａ４関連難聴を治療するための組成物及び方法 |
| TW202208406A (zh) | 2020-05-13 | 2022-03-01 | 美商阿科奧斯公司 | 用於治療ｋｃｎｑ４相關性聽力損失之組成物及方法 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| EP4271419A1 (en) | 2020-12-29 | 2023-11-08 | Akouos, Inc. | Compositions and methods for treating clrn1-associated hearing loss and/or vision loss |
| US20240277836A1 (en) | 2021-06-09 | 2024-08-22 | Chimeron Bio Corporation | Self-Amplifying RNA-Based VLP Vaccines |
| WO2022261343A1 (en) | 2021-06-09 | 2022-12-15 | Chimeron Bio Corporation | Peptide vlp-based vaccines |
| IL311572A (en) | 2021-09-30 | 2024-05-01 | Akouos Inc | Compositions and methods for treating kcnq4-associated hearing loss |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| AU2023215253A1 (en) | 2022-02-02 | 2024-09-19 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| TW202408545A (zh) | 2022-07-08 | 2024-03-01 | 美國貝勒醫學院 | 整合的壓力反應抑制劑及其使用方法 |
| AU2024266138A1 (en) | 2023-05-03 | 2025-11-13 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1004083A (en) | 1911-01-09 | 1911-09-26 | Henry Ritter | Method of making sash-bars and die for forming same. |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| JPH06503821A (ja) | 1990-12-20 | 1994-04-28 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | Ｂ型肝炎表面抗原に基づくワクチン |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| EP0817854A2 (en) | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
| US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
| US6902886B1 (en) | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| US20020052040A1 (en) | 1999-06-30 | 2002-05-02 | Nicholas Hunt | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| US20020177551A1 (en) | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| DE60233061D1 (de) | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| US20080115199A1 (en) * | 2001-12-06 | 2008-05-15 | Albert Young | Scheme for device and user authentication with key distribution in a wireless network |
| US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
| FR2862982B1 (fr) * | 2003-12-02 | 2006-04-28 | Genethon | Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale. |
| EP1734991A4 (en) | 2004-04-14 | 2012-10-24 | Avirid Inc | COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES |
| GB0426641D0 (en) | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| DE202006010918U1 (de) * | 2006-07-14 | 2006-10-05 | Flexi-Bogdahn Technik Gmbh & Co. Kg | Leineneinrichtung für eine mechanisch auf- und abrollbare Leine zum Führen von Tieren |
| EP2062246A4 (en) * | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| US20110250675A1 (en) * | 2008-03-26 | 2011-10-13 | Life Technologies Corporaiton | Virus-Like Particle Mediated Cellular Delivery |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| WO2011056899A2 (en) * | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| US9506041B2 (en) | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| CN113648406A (zh) | 2013-12-16 | 2021-11-16 | 美利坚合众国, 由健康及人类服务部部长代表 | 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法 |
-
2013
- 2013-03-15 US US14/388,441 patent/US9506041B2/en active Active
- 2013-03-15 EP EP19207297.3A patent/EP3663395B1/en active Active
- 2013-03-15 AU AU2013240248A patent/AU2013240248B2/en active Active
- 2013-03-15 WO PCT/US2013/031876 patent/WO2013148302A1/en not_active Ceased
- 2013-03-15 EP EP13712661.1A patent/EP2831225A1/en not_active Withdrawn
- 2013-03-15 JP JP2015503322A patent/JP2015527296A/ja active Pending
-
2016
- 2016-06-23 US US15/190,992 patent/US10538743B2/en active Active
-
2018
- 2018-06-12 JP JP2018111489A patent/JP6585237B2/ja active Active
-
2019
- 2019-03-19 AU AU2019201911A patent/AU2019201911A1/en not_active Abandoned
- 2019-12-10 US US16/709,147 patent/US20200102545A1/en not_active Abandoned
-
2021
- 2021-10-01 AU AU2021240286A patent/AU2021240286B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018186815A5 (enExample) | ||
| JP6585237B2 (ja) | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 | |
| JP2015527296A5 (enExample) | ||
| JP5572144B2 (ja) | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 | |
| EP1751289B1 (en) | Tc-83-derived alphavirus vectors, particles and methods | |
| US8961995B2 (en) | Methods and compositions for alphavirus replicons | |
| CA2410948C (en) | Method for the purification of alphavirus replicon particles | |
| Tubulekas et al. | Alphavirus expression vectors and their use as recombinant vaccines: a minireview | |
| JP2010530245A5 (enExample) | ||
| JP2017515509A (ja) | ワクチン用途のための高力価ウイルス様ベシクルの進化の方法 | |
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| JP2024512808A (ja) | Ｃａｌｒ及びｊａｋ２ｔ細胞受容体 | |
| Lundstrom | Alphaviruses as expression vectors | |
| Lundstrom | The potential of self-amplifying RNA vaccines for infectious diseases and COVID-19 | |
| US20080118956A1 (en) | Viral Particles Containing An Alphavirus-Derived Vector And Method For Preparing Said Viral Particle | |
| US20050221493A1 (en) | Recombinant virus production for the manufacturing of vaccines | |
| Dorange et al. | Vesicular stomatitis virus glycoprotein: a transducing coat for SFV‐based RNA vectors | |
| Aranda et al. | Recent patents on alphavirus protein expression and vector production | |
| Zhu et al. | Selection and characterization of packaging cell lines for XJ-160 virus | |
| WO2004056979A2 (en) | Recombinant virus production for the manufacturing of vaccines | |
| Polo et al. | Sindbis virus-based vectors for the study of class I antigen presentation in vitro and in vivo | |
| Lundstrom | RNA Viruses and Gene Therapy | |
| Yang et al. | Construction of nervous necrosis virus (NNV) genome-based DNA replicon vectors for the delivery of foreign antigens | |
| Wu-yang et al. | Research on basis of reverse genetics system of a Sindbis-like virus XJ-160 | |
| WO2024213051A1 (zh) | 一种saRNA递送系统及其制备方法和应用 |